Victoria Johnson

After 16 weeks of treatment, a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response.

Iron deficiency is currently screened at a ferritin threshold of 15 ug/mL, well below an accepted 25 ug/mL threshold.

A prospective study also found that the presence of psoriasis and dactylitis at disease onset were the strongest predictors for the development of PsA.

Davidow discussed how a new cohort study has helped support findings of an older European study and the need for a prospective trial to confirm the increased risk.

The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.

These findings, from an observational study, should be confirmed in a randomized, controlled trial.

Weisinger discussed findings from the largest cohort of patients with iTTP treated with Obinutuzumab.

Celltrion’s CT-P43/ustekinumab-stba has been approved under the name Steqeyma and is expected to launch in February 2025.

Matsushita discussed findings from the OLE FRONTIER4 study of Mim8.

Matino discussed data from the phase 3 BASIS study evaluating the recently approved Hympavzi.

Samelson-Jones discussed follow-up data of up to 6 years with investigations of fidanacogene elaparvovec.

Bernaudin discussed the Drepagreffe-1 and 2 studies and improvements seen over 10 years of follow-up.

Real-world clinical data from the Adelphi PNH II Disease Specific Programme were reported at ASH 2024.

Danicopan add-on therapy demonstrated more favorable safety in the ALPHA trial than pegcetacoplan did in the PEGASUS trial in a new analysis.

Appiah-Kubi also noted that despite elevated HbF levels, very young children with SCA already had anemia and reticulocytosis.

Pipe discussed findings from the open-label extension of the ATLAS studies at ASH 2024.

Chaturvedi discussed findings from the NeST study at ASH 2024, including an increased risk of stroke in those with silent cerebral infarction progression.

Piatek shared the latest data update from the phase 3 ALPHA study at the ASH 2024.

Frangoul discussed highlights from the latest data update from the CLIMB SCD-121 trial of Casgevy.

While the therapy was generally well-tolerated, the PIVOT trial failed its primary endpoint of dose-limiting toxicities.

The therapy uses a novel pyruvate kinase activator mechanism and warrants further investigation in an ongoing phase 3 trial.

Notably, participants without platelet responses also experienced improvements in fatigue, which may be due to the monoclonal antibody’s anti-inflammatory action.

The rheumatology month in review emphasizes new data from ACR 2024 in lupus, gout, and fibromyalgia.

The biosimilars month in review highlights new equivalency data for denosumab and tocilizumab biosimilars.

Pharmacokinetics and immunogenicity were also similar between reference tocilizumab and CT-P47.

Phase 1/2 data prompted the RMAT designation for HLHS shortly after Mesoblast announced positive phase 3 data for HFrEF.

Women who gave birth after infertility without receiving fertility treatments had an elevated risk of developing SARDs, such as lupus.

Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.

CDC, NIH, and AMA recommend PEMs to be at a 6th-to-8th-grade reading level, while assessed materials were readable at high school or higher levels.